How to Switch from Saxenda to Foundayo (Orforglipron)

Saxenda (liraglutide 3.0mg) was FDA-approved for weight management in 2014 — making it one of the oldest GLP-1 weight loss medications. While it was groundbreaking at launch, next-generation options like Foundayo surpass it in every measurable way:

Factor	Saxenda	Foundayo
Weight loss	5-8% (SCALE trials)	12.4% (ATTAIN-1)
Dosing	Daily injection	Daily pill
Monthly cost	$1,349/mo	$149-349/mo
Injection	Yes (daily subcutaneous)	No (oral tablet)
Cold storage	Before first use	None needed
FDA approval	2014	April 2026
Molecule	Liraglutide (peptide)	Orforglipron (non-peptide)
Half-life	13 hours	~29-49 hours

This is the easiest upgrade in GLP-1 medicine: More weight loss, lower cost, no injections, no needles, no cold storage. If you're still on Saxenda in 2026, it's time to switch.

While both are GLP-1 receptor agonists, the pharmacology differs significantly:

• Saxenda (liraglutide): First-generation peptide GLP-1 analogue. 97% homology to human GLP-1. Short half-life (13 hours) requiring daily injection. Moderate receptor activation.
• Foundayo (orforglipron): Non-peptide small molecule GLP-1 receptor agonist. Completely different chemical structure. Longer half-life (~29-49 hours). Can be taken orally because it doesn't degrade in the stomach.

Why Foundayo is more effective:

• Higher receptor occupancy at approved doses translates to greater appetite suppression
• Longer half-life provides more consistent GLP-1 receptor stimulation throughout the day
• Non-peptide structure allows higher effective doses via oral route

Think of it as upgrading from a flip phone to a smartphone — same basic function (GLP-1 activation), but everything else is better.

Liraglutide and orforglipron are different molecules, so there's no direct conversion. Start at Foundayo 0.8mg regardless of your Saxenda dose:

Saxenda Dose	Foundayo Start	Foundayo Target	Notes
0.6mg	0.8mg	2.5-5.5mg	Both starter doses
1.2mg	0.8mg	5.5-9mg	~8-12 weeks to target
1.8mg	0.8mg	9-14.5mg	~12-16 weeks
2.4mg	0.8mg	14.5-17.2mg	~16-20 weeks
3.0mg (max)	0.8mg	14.5-17.2mg	~16-20 weeks

Note on half-lives: Saxenda's liraglutide has a 13-hour half-life (vs Ozempic's 7-day half-life). This means liraglutide clears your system faster — within 2-3 days of stopping. The overlap with Foundayo's early doses provides sufficient coverage, but some patients notice a 1-2 day gap in appetite suppression during the transition.

Saxenda's side effect profile reflects its older, first-generation pharmacology. Foundayo's rates are higher but correspond to much greater efficacy:

• Nausea: Saxenda 39% → Foundayo 33.7% — improvement
• Diarrhea: Saxenda 21% → Foundayo 23.1% — similar
• Constipation: Saxenda 19% → Foundayo 25.4% — higher on Foundayo
• Vomiting: Saxenda 16% → Foundayo 24.0% — higher on Foundayo
• Injection site reactions: Saxenda 13.9% → Foundayo 0% — eliminated
• Headache: Saxenda 14% → Foundayo ~7% — improvement

Key advantage: Saxenda's daily injections cause injection site reactions in nearly 14% of patients — redness, itching, and bruising. Foundayo eliminates this entirely. Additionally, Saxenda's high nausea rate (39%) is actually worse than Foundayo's (33.7%), despite Saxenda's inferior weight loss results.

The cost savings from switching Saxenda to Foundayo are dramatic:

Saxenda: $1,349/month at list price. Novo Nordisk savings card may reduce this for insured patients.

Foundayo: $149-349/month (dose-dependent). Lilly savings card brings it to $25/month for commercially insured patients.

Annual savings at self-pay:

• Saxenda: $16,188/year
• Foundayo: $1,788-4,188/year
• You save: $12,000-14,400 per year

That's enough to fund a vacation, pay down debt, or invest in other health improvements — all while getting better weight loss results.

Hidden cost savings: No sharps containers, no cold storage needs, no injection supplies. Foundayo is just a pill in a bottle — no ancillary costs.